干细胞之家 - 中国干细胞行业门户第一站

 

 

搜索
干细胞之家 - 中国干细胞行业门户第一站 干细胞之家论坛 干细胞行业新闻 Hit-and-Run Action of Stem Cells Exploited for Targe ...
朗日生物

免疫细胞治疗专区

欢迎关注干细胞微信公众号

  
查看: 24376|回复: 0
go

Hit-and-Run Action of Stem Cells Exploited for Targeted Drug Delivery [复制链接]

Rank: 3Rank: 3

积分
385 
威望
385  
包包
1381  

优秀会员 金话筒

楼主
发表于 2013-10-9 09:13 |只看该作者 |倒序浏览 |打印
Scientists have inserted mRNA into mesenchymal stem cells (MSCs) to produce a drug-delivery vehicle. Following systemic administration, the modified MSCs targeted and adhered to sites of inflammation, then released interleukin-10 that significantly reduced local swelling.% [7 {: [3 r* v" \! F) ^! a- G
8 ]+ ^/ V3 R, m+ }) y7 d
Historically, MSC-based treatments have had mixed results. MSCs exert their therapeutic effects in hit-and-run style. That is, MSCs are rapidly cleared after entering the bloodstream, typically within a few hours or days. Yet, despite the transience of MSC therapeutic action, a team of scientists reports that it has engineered MSCs that rapidly localized at a distant site of inflammation in an in vivo model, and delivered therapeutically relevant concentrations of the drug. The MSCs had been engineered enhanced homing and the expression of interleukin-10, which is not inherently produced by MSCs.9 n7 i; ~5 m/ K. T
" u+ d' w. a; b' S
The team of scientists included members representing Brigham and Women’s Hospital, the Harvard Stem Cell Institute, MIT, and Massachusetts General Hospital. The team, which published the results of its proof-of concept study in the October 3 issue of Blood, notes that its work is already drawing interest from biopharmaceutical companies.
, T- }" _$ \, K& g6 G2 ^* y/ U  m: i
1 ~) Z: p2 q' ]$ G3 _7 r6 }“This opens the door to thinking of mRNA transfection of cell populations as next-generation therapeutics in the clinic, as they get around some of the delivery challenges that have been encountered with biological agents,” said Oren Levy, Ph.D., co-lead author of the study and instructor of medicine in the laboratory of research leader Jeffrey Karp, Ph.D. Dr. Karp, a Harvard Stem Cell Institute principal faculty member and associate professor at the Brigham and Women's Hospital, is also affiliated with Harvard Medical School and MIT.& q6 m* J2 `2 s0 g! @, w

1 {, C2 K  X' X2 \5 o“If you think of a cell as a drug factory, what we’re doing is targeting cell-based, drug factories to damaged or diseased tissues, where the cells can produce drugs at high enough levels to have a therapeutic effect,” said Dr. Karp.: E" i* [8 B; H7 |0 d+ y" M1 U
9 U# u% k$ y! V/ s& P  J# c9 ^
The key to success was the use of triple-transfected MSCs. In addition to expressing interleukin-1-, the cells expressed, in the team’s words, “functional rolling machinery.” This machinery consisted of P-selectin glycoprotein ligand-1(PSGL-1) and Sialyl-Lewisx (SLeX). Basically, the cells expressed both the immunomodulating agent and adhesive surface proteins.
9 n1 }' n3 s0 }; l( s; w" G
已有 1 人评分威望 包包 收起 理由
细胞海洋 + 2 + 10 极好资料

总评分: 威望 + 2  包包 + 10   查看全部评分

‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册
验证问答 换一个

Archiver|干细胞之家 ( 吉ICP备2021004615号-3 )

GMT+8, 2025-6-7 15:28

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.